A pharmacogenetic study of escitalopram in autism spectrum disorders

Autism Research

Volumn 3, Issue 1, 2010, Pages 1-7

  Owley, Thomas ^a,b   Brune, Camille W ^a   Salt, Jeff ^a,c   Walton, Laura ^a   Guter, Steve ^a   Ayuyao, Nelson ^a   Gibbons, Robert D ^a   Leventhal, Bennett L ^a   Cook, Edwin H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ST VINCENT S HOSPITAL   (United States)

^c Have Dreams   (United States)

Author keywords

Autistic disorder; Drug treatment; Escitalopram; Open label; Pharmacogenetics

Indexed keywords

ESCITALOPRAM;

ARTICLE; AUTISM; CHILD; CLINICAL TRIAL; DIPLOIDY; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; GENE INTERACTION; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE;

ADOLESCENT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD PLATELETS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; INTRONS; IRRITABLE MOOD; MALE; PERSONALITY ASSESSMENT; PHARMACOGENETICS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 77249129027     PISSN: 19393792     EISSN: 19393806     Source Type: Journal    
DOI: 10.1002/aur.109     Document Type: Article

References (32)

1. Aman, M.G., Singh, N.N., Stewart, A.W., & Field, C.J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485-491.
2. APA. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Association.
3. Benedetti, F., Colombo, C., Pontiggia, A., Bernasconi, A., Florita, M., & Smeraldi, E. (2003). Morning light treatment hastens the antidepressant effect of citalopram: A placebocontrolled trial. Journal of Clinical Psychiatry, 64, 648-653.
4. Buchsbaum, M.S., Hollander, E., Haznedar, M.M., Tang, C., Spiegel-Cohen, J., et al. (2001). Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: A pilot study. Int J Neuropsychopharmacol, 4, 119-125.
5. Cook, E.H., Rowlett, R., Jaselskis, C., & Leventhal, B.L. (1992). Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child & Adolescent Psychiatry, 31, 739-745.
6. Cross, S., Kim, S.J., Weiss, L.A., Delahanty, R.J., Sutcliffe, J.S., et al. (2008). Molecular genetics of the platelet serotonin system in first-degree relatives of patients with autism. Neuropsychopharmacology, 33, 353-360.
7. DeLong, G.R., Ritch, C.R., & Burch, S. (2002). Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Developmental Medicine and Child Neurology, 44, 652-659.
8. Hamer, R.M., & Simpson, P.M. (2009). Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. American Journal of Psychiatry, 166, 639-641.
9. Hedeker, D., & Gibbons, R.D. (2006). Longitudinal data analysis. Hoboken, NJ: Wiley.
10. Heils, A., Teufel, A., Petri, S., Stober, G., Riederer, P., et al. (1996). Allelic variation of human serotonin transporter gene expression. Journal of Neurochemistry, 66, 2621-2624.
11. Hellings, J.A., Kelley, L.A., Gabrielli, W.F., Kilgore, E., & Shah, P. (1996). Sertraline response in adults with mental retardation and autistic disorder. The Journal of Clinical Psychiatry, 57, 333-336.
12. Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., et al. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30, 582-589.
13. Hu, X.Z., Lipsky, R.H., Zhu, G., Akhtar, L.A., Taubman, J., et al. (2006). Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. American Journal of Human Genetics, 78, 815-826.
14. Jaselskis, C.A., Cook, E.H., & Fletcher, K.E. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12, 322-327.
15. Kim, S.J., Cox, N., Courchesne, R., Lord, C., Corsello, C., et al. (2002). Transmission disequilibrium mapping at the serotonin transporter gene (SLC6A4) region in autistic disorder. Molecular Psychiatry, 7, 278-288.
16. King, B.H., Wright, D., Handen, B.L., Sikich, L., Zimmerman, A.W., et al. (2001). Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 658-665.
17. King, B.H., Hollander, E., Sikich, L., McCracken, J.T., Scahill, L., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Archives of General Psychiatry, 66, 583-590.
18. Kirchheiner, J., Grundemann, D., & Schomig, E. (2006). Contribution of allelic variations in transporters to the phenotype of drug response. Journal of Psychopharmacology, 20, 27-32.
19. Laird, N.M., & Ware, J.H. (1982). Random-effects models for longitudinal data. Biometrics, 38, 963-974.
20. Lavori, P.W., Brown, C.H., Duan, N., Gibbons, R.D., & Greenhouse, J. (2008). Missing data in longitudinal clinical trials. Part A: design and conceptual issues. Psychiatric Annals, 38, 784-792.
21. Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24, 659-685.
22. Lord, C., Risi, S., Lambrecht, L., Cook, Jr., E.H., Leventhal, B.L., et al. (2000). The Autism Diagnostic Observation Schedule-Generic: A standard measure of social and communication deficits associated with the spectrum of autism. Journal of Autism and Developmental Disorders, 30, 205-223.
23. McDougle, C.J., Naylor, S.T., Cohen, D.J., Volkmar, F.R., Heninger, G.R., & Price, L.H. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53, 1001-1008.
24. McDougle, C.J., Epperson, C.N., Price, L.H., & Gelernter, J. (1998). Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Molecular Psychiatry, 3, 270-273.
25. McDougle, C.J., Scahill, L., McCracken, J.T., Aman, M.G., Tierney, E., et al. (2000). Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. Child and Adolescent Psychiatric Clinics of North America, 9, 201-224.
26. Namerow, L.B., Thomas, P., Bostic, J.Q., Prince, J., & Monuteaux, M.C. (2003). Use of citalopram in pervasive developmental disorders. Journal of Developmental and Behavioral Pediatrics, 24, 104-108.
27. Owley, T., Walton, L., Salt, J., Guter, Jr., S.J., Winnega, M., et al. (2005). An open-label trial of escitalopram in pervasive developmental disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 343-348.
28. Posey, D.J., Erickson, C.A., Stigler, K.A., & McDougle, C.J. (2006). The use of selective serotonin reuptake inhibitors in autism and related disorders. Journal of Child and Adolescent Psychopharmacology, 16, 181-186.
29. Risi, S., Lord, C., Corsello, C., Chrysler, C., Szatmari, P., et al. (2006). Combining information from multiple sources in the diagnosis of autism spectrum disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 1094-1103.
30. Siddique, J., Brown, C.H., Hedeker, D., Duan, N., Gibbons, R.D., et al. (2008). Missing data in longitudinal trials-Part B: Analytic issues. Psychiatric Annals, 38, 793-801.
31. Sugie, Y., Sugie, H., Fukuda, T., Ito, M., Sasada, Y., et al. (2005). Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. Journal of Autism and Developmental Disorders, 35, 377-385.
32. Zanardi, R., Magri, L., Rossini, D., Malaguti, A., Giordani, S., et al. (2007). Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression. European Neuropsychopharmacology, 17, 651-657.